Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluvastatin

Drug Profile

Fluvastatin

Alternative Names: Canef; Cranoc; Digaril; Fractal; Hovalin; Lescol; Lescol XL; Lipaxan; Lochol; Lymetel; Primesin; SRI 62320; Vastin; XU 62320

Latest Information Update: 21 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer AbbVie; Almirall S.A.; AstraZeneca; Bayer; Berenguer-Infale; Italfarmaco; Mitsubishi Tanabe Pharma Corporation; Novartis; Pierre Fabre; Reliant Pharmaceuticals; Sanofi; sanofi-aventis; Solvay
  • Class Antihyperlipidaemics; Indoles; Monounsaturated fatty acids
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia
  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Sep 2015 First Generic equivalent available in USA for Hyperlipidaemia
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top